Key Points
- PTC VP Mark Elliott Boulding sold 4,879 shares on January 7 at an average of $77.44 for $377,829.76 and has sold a total of 11,696 shares across recent trades (Nov. 17 and Jan. 5–7) worth roughly $896,526, reducing his stake by 3.98% to 117,659 shares valued at about $9.11M.
- The January transactions are part of broader insider selling disclosed in SEC filings that include the CEO, CFO, EVP and others, a pattern that could weigh on investor sentiment even if driven by personal diversification.
- PTCT trades near $76.85 (52-week range $35.95–$87.50) with a $6.17B market cap and 8.98 PE, and analysts maintain a consensus "Hold" rating with an average price target of $77.27.
PTC Therapeutics, Inc. (NASDAQ:PTCT - Get Free Report) EVP Lee Scott Golden sold 642 shares of the firm's stock in a transaction on Wednesday, January 7th. The stock was sold at an average price of $77.48, for a total value of $49,742.16. Following the completion of the transaction, the executive vice president owned 93,294 shares in the company, valued at approximately $7,228,419.12. This trade represents a 0.68% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.
Lee Scott Golden also recently made the following trade(s):
- On Tuesday, January 6th, Lee Scott Golden sold 1,340 shares of PTC Therapeutics stock. The stock was sold at an average price of $76.95, for a total value of $103,113.00.
PTC Therapeutics Stock Performance
PTC Therapeutics stock opened at $76.85 on Friday. PTC Therapeutics, Inc. has a one year low of $35.95 and a one year high of $87.50. The stock has a fifty day moving average of $76.43 and a 200 day moving average of $62.53. The stock has a market cap of $6.17 billion, a PE ratio of 8.98 and a beta of 0.49.
PTC Therapeutics (NASDAQ:PTCT - Get Free Report) last announced its earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.20 earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.19) by $1.39. The business had revenue of $211.01 million for the quarter, compared to analysts' expectations of $177.42 million. PTC Therapeutics had a negative return on equity of 194.11% and a net margin of 42.25%.The business's revenue for the quarter was up 7.2% on a year-over-year basis. During the same period last year, the firm posted ($1.39) earnings per share. As a group, sell-side analysts predict that PTC Therapeutics, Inc. will post -4.52 EPS for the current fiscal year.
Analysts Set New Price Targets
PTCT has been the subject of a number of research reports. Citigroup upped their target price on shares of PTC Therapeutics from $50.00 to $75.00 and gave the company a "neutral" rating in a report on Wednesday, November 5th. Barclays boosted their price objective on shares of PTC Therapeutics from $46.00 to $68.00 and gave the company an "equal weight" rating in a research report on Wednesday, November 5th. Cowen reaffirmed a "hold" rating on shares of PTC Therapeutics in a report on Wednesday, November 5th. TD Cowen lifted their target price on PTC Therapeutics from $50.00 to $63.00 and gave the company a "hold" rating in a research report on Wednesday, November 5th. Finally, Wall Street Zen raised PTC Therapeutics from a "hold" rating to a "buy" rating in a report on Saturday, January 3rd. Nine investment analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus target price of $77.27.
View Our Latest Stock Report on PTC Therapeutics
Institutional Investors Weigh In On PTC Therapeutics
A number of institutional investors have recently bought and sold shares of PTCT. Wealth Enhancement Advisory Services LLC lifted its position in shares of PTC Therapeutics by 9.7% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 9,145 shares of the biopharmaceutical company's stock valued at $701,000 after acquiring an additional 806 shares in the last quarter. GAMMA Investing LLC raised its stake in PTC Therapeutics by 160.0% during the 4th quarter. GAMMA Investing LLC now owns 1,451 shares of the biopharmaceutical company's stock valued at $110,000 after purchasing an additional 893 shares during the period. IFP Advisors Inc lifted its holdings in shares of PTC Therapeutics by 68.1% in the third quarter. IFP Advisors Inc now owns 765 shares of the biopharmaceutical company's stock worth $47,000 after buying an additional 310 shares in the last quarter. Cambria Investment Management L.P. increased its holdings in PTC Therapeutics by 24.9% in the 3rd quarter. Cambria Investment Management L.P. now owns 11,634 shares of the biopharmaceutical company's stock valued at $714,000 after acquiring an additional 2,322 shares during the last quarter. Finally, CIBC Bancorp USA Inc. bought a new stake in PTC Therapeutics in the 3rd quarter valued at $508,000.
PTC Therapeutics News Roundup
Here are the key news stories impacting PTC Therapeutics this week:
- Neutral Sentiment: Analysts maintain a consensus rating of "Hold" on PTCT, signaling muted broker enthusiasm and limited near-term upward catalyst from Wall Street. Article Title
- Neutral Sentiment: PTC reported an inducement grant of 300 restricted stock units for a new non-executive hire under Nasdaq Rule 5635(c)(4); a routine, small hire award with minimal direct financial impact but modest dilution. Article Title
- Negative Sentiment: A company director executed a sizable sale valued at $916,200, a notable insider disposition that can weigh on investor sentiment even if done for personal reasons. Article Title
- Negative Sentiment: Broad insider selling disclosed in SEC Form 4 filings: multiple senior executives (including CEO Matthew B. Klein, CFO Pierre Gravier, EVP Lee Golden, VP Mark Boulding, CAO Christine Utter and others) sold shares in early January. These trades—ranging from small lots to multi-thousand-share sales—represent notable reductions in insider positions and may signal profit-taking or diversification, which can pressure the stock until a clear operational/strategy signal offsets them. Representative filings: SEC Form 4
PTC Therapeutics Company Profile
(
Get Free Report)
PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule and biologic therapies for the treatment of rare genetic disorders. Since its founding in 1998, PTC has dedicated its efforts to addressing high unmet medical needs by targeting underlying genetic causes of disease. The company's research platform emphasizes mechanisms such as nonsense suppression and RNA modulation, enabling the development of novel treatments for conditions with limited therapeutic options.
Among PTC's approved products is Translarna (ataluren), a first-in-class therapy designed to treat nonsense mutation Duchenne muscular dystrophy in select markets.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
